OptiNose — Q1 2024 Earnings Presentation
17 slides from OptiNose's earnings presentation, May 14, 2024
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 14, 2024
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Today's Agenda
3 Today’s Agenda Introduction, Key Takeaways and CS Launch Update Ramy Mahmoud, MD, MPH Q1 2024 Performance and FY 2024 Financial Guidance Jonathan Neely Closing Remarks Ramy Mahmoud, MD, MPH
Slide 4: Key Takeaways
4 Key Takeaways • New indication creates a significant near-term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current specialty sales force of 75 reps, and phased modest incremental commercial investment, sufficient to achieve p
Slide 5: Post Offering Cash Expected to Fund Operations and Debt Service Through 2025
5 Post Offering Cash and Cash Equivalents of ~$100 Million Expected to Fund Operations and Debt Service Obligations Through 2025 Recent $55 million raised in a registered direct offering, priced "at the market" on May 8th • Post-offering cash and cash equivalents of ~$100 million • Sufficient to fun
Slide 6: CS Launch Updates
epee CS Launch Updates
Slide 7: Q2 Planned Launch Activities to Drive New Growth
7 Attending 10 National and 20 Regional ENT and Allergy Specific Congresses Exhibits/Booth Product Theaters Promotional Dinner Programs Sales Force Congress Activity Non-Personal Promotion Peer-to-Peer Education 75 Sales Reps Deployed 35K Total Sales Calls >150 CS Peer-to-Peer Speaker Programs reach
Slide 8: Q1 2024 Performance
epee Q1 2024 Performance
Slide 9: Financial Review – First Quarter 2024
9 Financial Review – First Quarter 2024 Average net revenue per prescription increased 63% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $14.9 million exceeded initial financial guidance and Operating Expenses decreased ~$3M compared to Q1 2023 $24.5 $21.7 Q1
Slide 10: 2024 Outlook
epee 2024 Outlook
Slide 11: Full Year 2024 Financial Guidance
11 Full Year 2024 Financial Guidance GAAP Operating Expenses (SG&A and R&D Expenses) Expected to be between $95 to $101 million; approximately $6 million of which represents stock-based compensation XHANCE Net Revenue FY 2024 expected to be between $85 to $95 million XHANCE Average Net Revenue per P
Slide 12: Closing Remarks
Closing Remarks
Slide 13: Optinose – Financial Outlook for XHANCE in Chronic Sinusitis
13 Optinose – Financial Outlook for XHANCE in Chronic Sinusitis Our Leadership team is focused on meeting or exceeding these objectives Growth With the new CS indication XHANCE has peak net revenue potential of at least $300M in specialty physician audience Efficiency XHANCE launching into greatly e
Slide 14: Optinose – Incremental Growth Opportunities
14 Optinose – Incremental Growth Opportunities Additional growth potential exists both within and beyond our current ENT/Allergy audience Expand in Specialty: We believe there are ROI positive opportunities to expand sales territories (to as many as ~115) in ENT and Allergy based on success/capital
Slide 15: Key Takeaways
15 Key Takeaways • New indication creates a significant near-term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current specialty sales force of 75 reps, and phased modest incremental commercial investment, sufficient to achieve
Slide 16: Investor Relations – Optinose
16 Investor Relations – NASDAQ: OPTN Optinose Investor ContactAnalyst Coverage 1 Jefferies: Glen Santangelo Lake Street: Thomas Flaten Piper Sandler: David Amsellem H. C. Wainwright: Matthew Caufield 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or f
Slide 17: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 14, 2024